Breaking News

Mabwell Bioscience, Aditum Bio Form Kalexo Bio 

Aims to advance siRNA therapy for cardiovascular disorders.

Mabwell (Shanghai) Bioscience Co., Ltd. and Aditum Bio have launched Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop 2MW7141, a dual-target siRNA candidate for lipid management in patients with dyslipidemia and for the prevention of high-risk atherosclerotic cardiovascular disease (ASCVD) events. Aditum Bio will provide funding for Kalexo Bio, and the parties will collaborate to advance 2MW7141 into clinical development. Kalexo Bio was fou...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters